Epilepsy Therapeutic Pipeline H1 2015 Review Research Report

DALLAS, March 4, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Epilepsy - Pipeline Review, H1 2015" therapeutic market research report of 330 pages with latest updates, data and information to its online business intelligence library.

The report Epilepsy Pipeline Review, H1 2015 provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Epilepsy is a brain disorder in which clusters of nerve cells, or neurons, in the brain sometimes signal abnormally. Epilepsy is not contagious and is not caused by mental illness or mental retardation. Epilepsy has many possible causes, from illness to brain damage to abnormal brain development. Genetics may also play a role. Epilepsy can be caused by different conditions that affect a person's brain. Some known causes include stroke, brain tumor, neurocysticercosis, head injury, loss of oxygen to the brain and other neurologic diseases. Symptoms vary from person to person.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include: Acorda Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Advicenne Pharma, Aeolus Pharmaceuticals, Inc., Aestus Therapeutics, Inc., Alexza Pharmaceuticals, Inc., Allergan, Inc., Anavex Life Sciences Corp., Asklepios BioPharmaceutical, Inc., Astellas Pharma Inc., Bial - Portela & Ca, S.A., BioCrea GmbH, Bionomics Limited, Biovista Inc., Catalyst Pharmaceutical Partners, Inc., Celentyx Ltd., Chong Kun Dang Pharmaceutical Corp., Concert Pharmaceuticals, Inc., Convergence Pharmaceuticals Ltd., D-Pharm Ltd., Desitin Arzneimittel GmbH, Eisai Co., Ltd., Epirus Biopharmaceuticals, Inc., Glialogix, Inc., GW Pharmaceuticals plc, H. Lundbeck A/S, INSYS Therapeutics, Inc., Iproteos S.L., Knopp Biosciences LLC, Ligand Pharmaceuticals, Inc., Lipicard Technologies Limited, Lohocla Research Corporation, Marathon Pharmaceuticals, LLC, MarcoPolo Pharmaceuticals SA, Marinus Pharmaceuticals, Inc., MedGenesis Therapeutix Inc., Neurocrine Biosciences, Inc., Novartis AG, Pfizer Inc., PharmatrophiX, Inc., RestorGenex Corporation, Retrophin Inc., Sage Therapeutics, Saniona AB, SciFluor Life Sciences, LLC, SK Biopharmaceuticals Co., Ltd., UCB S.A., Ultragenyx Pharmaceutical Inc., Upsher-Smith Laboratories, Inc., Vichem Chemie Research Ltd., VistaGen Therapeutics, Inc., Zynerba Pharmaceuticals, Inc.

Order a Purchase copy of this report @http://www.rnrmarketresearch.com/contacts/purchase?rname=308834 . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: 2-DG, ADD-405008, ADS-8800 Series, ADV-5803, ADV-6208, ADV-6769, ADV-6770, AEOL-1114B, AEOL-11203, AEOL-11207, alprazolam, ANAVEX-2-73, AV-101, AVL-5189, BNP-TLE, brivaracetam, BVA-601, C-10068, cannabidiol, carbamazepine, carisbamate, CCG-63802, Cell Therapy for Parkinson's Disease and Epilepsy, CHEC-9, CKD-903, CNV-1061436, cosyntropin, CPP-115, CX-1010, diazepam, DP-VPA, Drug for Epilepsy, Drug to Agonize GABA Receptor for Epilepsy, Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders, EMSP, Epidiolex, ESB, ESBB, eslicarbazepine acetate, everolimus, fosphenytoin sodium, FV-082, FV-137, ganaxolone, Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy, GLX-1112, GWP-42003-P, GWP-42006, IPR-003, KM-113, KM-314, lacosamide, lamotrigine, levetiracetam, levetiracetam, liatermin, LT-4121, LT-4122, LT-4123, LT-4124, LT-4125, LT-4126, MB-003, midazolam hydrochloride, MRS-5474, MSP, naluzotan, NB-23R1, NGT-168, P-529, perampanel, PF-04895162, PRTT-200, Remegal, rufinamide, SAGE-217, SAGE-547, SAGE-689, SCT-66, selurampanel, SF-0034, SGE-102, Small Molecules to Agonize GABA-A Receptor For Epilepsy, Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism, Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System, Small Molecules to Antagonize TLR-4 for CNS Disorders, Small Molecules to Inhibit Dynamin for Epilepsy and Oncology, sulthiame, TG-4155, tonabersat, topiramate, UBP-608, UX-007, VAD-1, VAD-2, VB-3323, VID-45110, VLB-01, VU-0456810, YKP-3089, Z-944, ZYN-002 and etc.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Epilepsy
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Neurology Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/neurology-drugs .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: 

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus:https://plus.google.com/u/0/104156468549256253075/

Twitter:https://twitter.com/RnRMR

Facebook:http://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed